(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
The Magnificence of Extraordinariness: Presenting Valuable Adornments and Gemstones- $2,000 tariff rebate checks? 50-year mortgages? Making sense of Trump's new 'affordability' proposals.
- Find the Mysteries of Powerful Using time productively: Augmenting Efficiency and Proficiency
- Robert Irwin on winning 'Dancing With the Stars' 10 years after sister Bindi: 'This was everything I dreamed it would be and so much more'
- One perk to marrying Richard Marx later in life? 'We don't have time' for stupid arguments, says Daisy Fuentes.
- The Job of a Migration Legal advisor: How They Can Help You
- 7 Delightful Ferris Wheels, Do You Like Them?
- Tracking down the Right Equilibrium: Charges versus Personal Costs in Senior Protection.
- Visiting This Japanese City Just Got A Little More Expensive (Here's What Travelers Should Know)
